ATM and cancer: This vulnerability is being investigated in multiple cancer types through the development of ATM inhibitors [118] and specifically in PDAC patients with germline BRCA1/2 mutations using the PARP inhibitor Olaparib [119,120], which provides some optimism for future patient outcomes.